H. Lundbeck A/S Class A HLUN_A
OMXCOP · Denmark · Health Technology
DKK 41.45-1.25 (-2.93%)
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Investing.com -- H Lundbeck (LON:0ND5) has expressed interest in a potential takeover of Chicago-based commercial-stage drugmaker Xeris Pharmaceuticals Inc (NASDAQ:XERS), according to people familiar with the matter cited by Bloomberg. The Danish pharmaceutical group has been working with financial advisers to explore an acquisition of the U.S. firm, though discussions remain preliminary and may not result in a formal transaction.
H. Lundbeck (CPSE:HLUN B) has just secured Japanese marketing authorization for eptinezumab in migraine prevention, a fresh regulatory milestone that broadens its neuroscience footprint and adds another data point for investors watching the stock. The eptinezumab approval lands at a time when H. Lundbeck’s recent news flow also includes the randomization milestone in its Phase III bexicaserin epilepsy program and a plan to shift its US base to Greater Boston to build out a global innovation...
Vyepti and Rexulti lead strong H1 performance, while the company navigates competitive pressures and prepares for key Phase III readouts.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.